Immune-mediated myasthenia gravis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:26:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Immune-mediated myasthenia gravis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Descartes-08 compared to placebo in adults with generalized myasthenia gravis https://clinicaltrials.eu/trial/study-of-descartes-08-compared-to-placebo-in-adults-with-generalized-myasthenia-gravis/ Wed, 29 Apr 2026 15:07:11 +0000 https://clinicaltrials.eu/trial/study-of-descartes-08-compared-to-placebo-in-adults-with-generalized-myasthenia-gravis/ This study focuses on Generalized Myasthenia Gravis, a rare autoimmune disease that causes muscle weakness and fatigue affecting daily activities. The investigation examines a new treatment called Descartes-08, which consists of modified immune cells (specifically CD8+ T lymphocytes) that have been engineered to target specific proteins involved in the disease process.

The research aims to determine if Descartes-08 can improve the ability to perform daily activities in people with Generalized Myasthenia Gravis. The treatment is administered through intravenous infusion, and participants will receive either Descartes-08 or placebo. The study will monitor patients for 4 months to assess changes in their symptoms and ability to perform everyday tasks.

The medication being tested is a type of cell therapy that uses the patient’s own immune cells that have been modified in a laboratory. These cells are specifically designed to target and fight the mechanisms causing muscle weakness in Generalized Myasthenia Gravis. Throughout the study, participants will undergo regular evaluations to measure their muscle strength and daily functioning abilities.

]]>